Apr 3, 2021 by Patrick Bafuma3 Cancer Diagnostic Monster Stocks on SaleThese under-the-radar stocks have had incredible growth over the last 5 years, and are all off over 15% from their highs.
Apr 2, 2021 by Patrick BafumaThis Pharma Can Breathe New Life Into Your PortfolioWill future Tyvaso revenue growth push United Therapeutics to new heights?
Apr 2, 2021 by Patrick BafumaThis 2020 Biotech IPO Is Poised to Break Out in 2021Revolution Medicines' leading compound is shaping up to be a platform in a pill.
Apr 1, 2021 by Patrick BafumaBetter Buy for the Next 10 Years: Abiomed vs. Guardant HeathWhich healthcare company is a better play for the next decade?
Apr 1, 2021 by Patrick BafumaThis Big Leap in Cancer Treatment Could Change the LandscapeTIL therapy looks able to win a large addressable market, and Iovance is the leader of the pack.
Mar 29, 2021 by Patrick Bafuma2,500% Returns? This Stock Is Like Buying Illumina in 200710x Genomics is powering the next generation of biotech research.
Mar 21, 2021 by Patrick Bafuma3 Reasons to Buy Sage Therapeutics, and 1 Reason to PassCan this brain health-focused biotech continue to rise, or will it fade -- again?
Mar 18, 2021 by Patrick BafumaWhy bluebird bio Is Worth a Look TodayIt's good news for investors as this biotech brings impressive results to the rare disease market.
Mar 16, 2021 by Patrick Bafuma3 Reasons to Avoid Arena Pharmaceuticals -- and 1 Reason to BuyCan this pharma blow past its highs from 10 years ago, or will it fade away -- again?
Mar 11, 2021 by Patrick BafumaThis Underperforming Biotech Is Ready to Beat the MarketIncyte is betting bigger on ruxolitinib to bring back growth.
Mar 9, 2021 by Patrick BafumaBeyond COVID, Regeneron Is Betting Big on OncologyFuture growth will depend on its new checkpoint inhibitor wrangling market share away from Merck's Keytruda.
Mar 4, 2021 by Patrick BafumaGet an Earful of This Growing Healthcare StockEargo is looking to modernize the hearing aid market, and we're all ears.
Mar 3, 2021 by Patrick BafumaLike Guardant Health? You'll Love CareDxThis under-the-radar diagnostics company is thriving yet reasonably priced.
Feb 27, 2021 by Patrick BafumaMagenta Is Ready to Paint Your Portfolio GreenThis clinical-stage biotech is looking to make stem cell transplantation faster, easier, and safer for both donors and patients.
Feb 23, 2021 by Patrick BafumaWhy Turning Point Is Turning HeadsThis oncology biotech is up over 450% since its April 2019 IPO. Are there still gains to come, or should investors turn away?
Feb 20, 2021 by Patrick BafumaIt's Already Doubled in 2021, and This Healthcare Juggernaut Is Just Getting StartedDermtech stock is up over 130% so far in 2021, and increased insurance acceptance is just one reason it could be a five-bagger in the next five years.
